Pediatric Antibiotic Overuse: What the Evidence Shows About Pushing Back on "Just in Case" Prescribing
Synthesising 12 key studies — including a 2024 JAMA Network Open prescribing analysis, an AAP national QI collaborative, systematic reviews of stewardship programmes, and a cluster RCT — to equip clinicians with the evidence for rational antibiotic use in children, through 2026
This is an original evidence synthesis. See References for source studies.
One-Minute Takeaway
One-Minute Takeaway
- Pediatric antibiotic overuse is pervasive: a 2024 cross-sectional analysis of over 500,000 outpatient prescriptions in Tennessee found that only 31.4% were optimal for both antibiotic choice and duration, and 39% were prescribed for diagnoses that rarely require antibiotics (Lehrer et al. 2024).
- Antimicrobial stewardship programmes (ASPs) consistently reduce antibiotic use in paediatric settings. A systematic scoping review of 113 studies confirmed that ASPs decrease prescribing without worsening clinical outcomes, and a 2024 AAP national QI collaborative across 118 hospitals demonstrated significant improvements in empirical, definitive, and duration-appropriate prescribing for three common infections (Donà et al. 2020; McCulloh et al. 2024).
- A cluster RCT in Tanzanian primary care demonstrated that a digital clinical decision support algorithm reduced paediatric antibiotic prescriptions from 70.1% to 23.2% of encounters without increasing clinical failure — providing the strongest evidence to date that dramatically reducing antibiotic use in children is both achievable and safe (Shao et al. 2023).
- Outpatient stewardship remains the weakest link: most ASP evidence comes from inpatient settings, while the vast majority of unnecessary paediatric antibiotic prescriptions originate in outpatient clinics, emergency departments, and urgent care — particularly for acute respiratory tract infections where viral aetiology predominates.
Why This Topic Matters
Antibiotics are the most commonly prescribed medications to children worldwide. In the United States alone, paediatric emergency departments generate approximately 7 million antibiotic prescriptions annually — and by multiple estimates, roughly half of those are unnecessary or inappropriate. The consequences of this overuse extend far beyond the individual child: antimicrobial resistance now ranks among the leading threats to global public health, with multidrug-resistant infections costing an estimated $29,000 per episode and contributing to excess morbidity and mortality across all age groups.
Yet for the individual clinician, the pressure to prescribe "just in case" is intense. Parents expect treatment when they bring a sick child to the clinic. Diagnostic uncertainty is inherent — especially in young children who cannot articulate symptoms clearly. Time constraints discourage the longer conversations required to explain why an antibiotic is not needed. And medicolegal anxiety drives a defensive reflex toward treatment. The result is a systematic gap between what the evidence supports and what actually gets prescribed — a gap that stewardship programmes are designed to close.
What Evidence Was Reviewed
This synthesis draws on 12 key publications from 2017 to 2025, including the AAP policy statement on paediatric antibiotic stewardship, national and international systematic reviews, a landmark cluster RCT, multi-centre QI collaboratives, and large cross-sectional prescribing analyses. Together, these sources address the scope of overuse, the evidence for specific stewardship interventions, and the emerging evidence for condition-specific shorter treatment courses.
| Study | Design | n | Focus | Key Finding | Quality |
|---|---|---|---|---|---|
| Lehrer et al. 2024 | Cross-sectional (claims data) | 506633 | Outpatient prescribing, Tennessee | Only 31.4% optimal for choice + duration; 39% for rarely-needed diagnoses | High |
| McCulloh et al. 2024 (AAP VIP Network) | Multi-centre QI collaborative | 118 hospitals | Inpatient CAP, SSTI, UTI | Significant improvement in empirical, definitive, and duration-appropriate prescribing | High |
| Hersh et al. 2021 (AAP Policy) | Policy statement | NR | Pediatric antibiotic stewardship | Framework for inpatient + outpatient ASP; core strategies defined | High |
| Donà et al. 2020 | Systematic scoping review | 113 studies | Paediatric ASPs globally | ASPs consistently reduce antibiotic use; limited outpatient evidence | High |
| Brigadoi et al. 2023 | Systematic review | NR | ASPs in paediatric ED + primary care | Half of prescriptions unnecessary; ASPs reduce prescribing rates | High |
| Shao et al. 2023 (ePOCT+) | Cluster RCT | 44306 | Digital CDS in Tanzanian primary care | Antibiotics: 23.2% vs 70.1%; noninferior clinical outcomes | High |
| Gerber et al. 2017 | Cluster RCT | 30139 | Broad- vs narrow-spectrum for paediatric ARIs | Narrow-spectrum antibiotics had comparable outcomes; fewer adverse events | High |
| Williams et al. 2022 (SCOUT-CAP) | RCT | 380 | Short- vs standard-course antibiotics for paediatric CAP | 5 days noninferior to 10 days for outpatient CAP | High |
| Pernica et al. 2021 (SAFER) | RCT | 281 | Short-course antimicrobials for paediatric CAP | 5-day course noninferior to 10-day course | High |
| Dillen et al. 2024 | Systematic review & meta-analysis | NR | Factors associated with inappropriate prescribing | Diagnostic uncertainty, parental expectation, and time pressure as key drivers | High |
| Tribble et al. 2024 | Before-and-after study (2 hospitals) | NR | Dedicated paediatric ASPs within combined hospitals | Sustained decrease in paediatric antibiotic use after dedicated ASP | Moderate |
| Donà et al. 2025 | Narrative review | NR | ASP and diagnostic stewardship in paediatrics | Complementary impact of ASP + DSP; multidisciplinary approach essential | Moderate |
Key Findings in Pediatric Antibiotic Overuse
The Scale of the Problem: How Bad Is "Just in Case"?
The scope of paediatric antibiotic overuse is well quantified and remarkably consistent across settings. The Lehrer 2024 analysis of over half a million outpatient prescriptions in Tennessee — a high-prescribing state — found that only 31.4% met guidelines for both appropriate antibiotic choice and appropriate duration. Fully 39% of prescriptions were for conditions classified as "tier 3" diagnoses — those that rarely, if ever, require antibiotics — including viral upper respiratory infections, bronchiolitis, and non-specific cough. A cross-sectional European study of 28 paediatric emergency departments reported that 19–64% of children across centres received antibiotics inappropriately. The systematic review by Brigadoi and colleagues estimated that approximately half of all paediatric antibiotic prescriptions worldwide are unnecessary or inappropriate.
Acute respiratory tract infections are the primary driver. Data from the CDC confirm that the common cold, non-specific upper respiratory infection, acute bronchitis, and bronchiolitis are among the most common diagnoses associated with paediatric antibiotic prescriptions — despite being overwhelmingly viral in origin. Acute otitis media (AOM) and pharyngitis are conditions that may warrant antibiotics, but even here, overuse persists: the Lehrer analysis found that suboptimal antibiotic choice for AOM and pharyngitis alone — particularly the use of broad-spectrum agents when amoxicillin is guideline-recommended — accounted for a large share of avoidable prescribing.
What Works: Stewardship Interventions with Evidence
The evidence for antimicrobial stewardship programmes in paediatric settings is substantial and consistent. The Donà 2020 systematic scoping review identified 113 studies of paediatric ASPs globally and found that these programmes consistently reduced antibiotic use across inpatient settings without adverse clinical outcomes. The most common and effective strategies included prospective audit with feedback (a designated stewardship team reviewing antibiotic orders and providing real-time recommendations), clinical decision support integrated into electronic health records, and education combined with academic detailing.
The McCulloh 2024 national QI collaborative — conducted across 118 hospitals in the AAP Value in Inpatient Pediatrics Network — provides the largest-scale implementation evidence to date. Focusing on three high-volume conditions (community-acquired pneumonia, skin and soft tissue infections, and urinary tract infections), the initiative used standardised order sets, audit with feedback, and clinician education to significantly improve the proportion of children receiving guideline-concordant empirical therapy, appropriate definitive therapy, and evidence-based duration. This multi-site success demonstrates that stewardship improvement is achievable at scale with structured quality improvement methodology.
The strongest experimental evidence for reducing paediatric antibiotic overuse comes from the ePOCT+ cluster RCT in Tanzania. This trial randomised 40 primary care facilities to either a digital clinical decision support algorithm (ePOCT+, combining a tablet-based assessment tool with C-reactive protein testing, haemoglobin measurement, and pulse oximetry) or usual care. Over 11 months and more than 44,000 consultations, the intervention reduced antibiotic prescribing from 70.1% to 23.2% of encounters — a staggering 46.4 percentage point reduction — without increasing day-7 clinical failure.
While the absolute prescribing rates in this low-resource setting are higher than typical high-income country baselines, the magnitude of the effect and the noninferior clinical outcomes provide powerful proof of concept: the majority of paediatric antibiotic prescriptions can be safely withheld when clinical decision-making is systematically supported. The integration of point-of-care CRP testing was a key component, helping clinicians distinguish bacterial from viral infections at the bedside — a strategy that multiple systematic reviews have identified as promising for outpatient paediatric stewardship.
One of the most actionable findings in recent paediatric infectious disease research is that shorter antibiotic courses are noninferior to traditional longer courses for several common conditions. Two landmark RCTs — SCOUT-CAP (Williams et al. 2022) and SAFER (Pernica et al. 2021) — independently demonstrated that 5-day antibiotic courses for outpatient community-acquired pneumonia in children were noninferior to the traditional 10-day courses. These findings directly challenge the default 10-day prescriptions that remain standard in many practices.
Similarly, evidence supports shorter courses for uncomplicated urinary tract infections and skin and soft tissue infections in children. The Lehrer 2024 analysis found that excessive duration — not inappropriate choice — was the dominant contributor to suboptimal prescribing for many conditions. Simply defaulting to shorter, evidence-based durations for CAP, UTI, and SSTI would substantially reduce total antibiotic exposure without compromising outcomes. Electronic health record systems can facilitate this by pre-populating shorter default durations in order sets.
The Gerber 2017 cluster RCT across 31 primary care practices enrolled over 30,000 children with acute respiratory infections and compared outcomes between practices prescribing predominantly broad-spectrum versus narrow-spectrum antibiotics. Narrow-spectrum prescribing (primarily amoxicillin) was associated with comparable treatment success and significantly fewer adverse events — including lower rates of diarrhoea and allergic reactions — compared to broad-spectrum alternatives.
This trial provides direct evidence against the "just in case, use the bigger gun" mentality. For the most common paediatric indications — AOM, streptococcal pharyngitis, and outpatient pneumonia — amoxicillin remains the evidence-based first-line agent. Broad-spectrum antibiotics such as amoxicillin-clavulanate, azithromycin, and cephalosporins should be reserved for specific clinical scenarios (treatment failure, known resistance, true penicillin allergy) rather than used as defaults to "cover more."
A systematic review and meta-analysis by Dillen and colleagues (2024) identified parental expectation, diagnostic uncertainty, and time pressure as the three most consistent factors associated with inappropriate paediatric antibiotic prescribing in high-income outpatient settings. Addressing these drivers requires communication strategies, not just clinical knowledge.
Evidence-based approaches include: providing a specific diagnosis name for the viral illness (parents respond better to "Your child has croup" than "It's just a virus"), offering a concrete management plan with timed follow-up ("Here's what to watch for, and I want you to call or return in 48 hours if these three things happen"), and using contingency prescriptions — sometimes called "delayed prescriptions" — where the clinician writes a prescription but instructs the family to fill it only if symptoms worsen after a defined waiting period. RCTs of delayed prescribing for paediatric AOM have demonstrated that the majority of families never fill the prescription, while parental satisfaction remains high because they feel they have a safety net. The AAP policy statement also recommends watchful waiting as a first-line strategy for mild AOM in children over two years.
Quality & Consistency of Evidence
What the Evidence Does Not Show
The most critical gap is the lack of robust RCT evidence for outpatient antibiotic stewardship interventions in high-income paediatric settings. While inpatient ASPs are well studied, outpatient practice — where the vast majority of inappropriate prescribing occurs — is supported mainly by observational studies and before-and-after designs. The ePOCT+ trial is a notable exception but was conducted in a low-resource context with fundamentally different baseline prescribing patterns. Whether similar digital decision support tools would achieve comparable reductions in settings where baseline prescribing is already lower remains untested.
The impact of ASPs on antimicrobial resistance at the community level has not been conclusively demonstrated in paediatric populations. While the biological rationale is strong and indirect evidence supports the link between reduced antibiotic use and lower resistance rates, direct demonstration that paediatric stewardship programmes measurably reduce resistance prevalence requires long-term surveillance studies that are largely absent from the current evidence base.
Equity concerns remain under-studied. The Lehrer 2024 analysis found that children in areas with higher social vulnerability were less likely to receive optimal antibiotic prescriptions — suggesting that stewardship interventions may need to be specifically designed to avoid widening disparities. Similarly, most ASP evidence originates from the United States and Europe, with limited data from low- and middle-income countries where antibiotic overuse rates are highest and stewardship infrastructure is least developed.
Practical Implications
Based on the current evidence, the following considerations reflect areas where the data most clearly inform how clinicians can reduce unnecessary paediatric antibiotic prescribing. These are evidence-based considerations — clinical judgement, local resistance patterns, and individual patient factors remain essential.
The single most impactful intervention is withholding antibiotics for conditions that are overwhelmingly viral — common cold, bronchiolitis, non-specific cough, viral pharyngitis. This step alone would eliminate the largest category of unnecessary prescriptions. Naming the specific viral diagnosis, providing a symptom management plan, and offering clear return precautions increases parental acceptance.
For AOM, streptococcal pharyngitis, and outpatient CAP, amoxicillin is the guideline-recommended first-line agent. Broad-spectrum alternatives carry higher adverse event rates without improved efficacy. "Saving" broader agents for documented treatment failure or specific clinical scenarios preserves both individual benefit and population-level resistance profiles.
Five-day courses for outpatient paediatric CAP are noninferior to 10-day courses across two RCTs. Defaulting to shorter, evidence-based durations — and embedding these into EHR order sets — represents a low-effort, high-yield change. Every day of unnecessary antibiotic exposure carries incremental risk of adverse effects and resistance selection.
For mild AOM in children over two years and for selected other conditions with diagnostic uncertainty, watchful waiting with a contingency ("delayed") prescription is an evidence-based strategy that reduces antibiotic fills while maintaining parental confidence. Most families do not fill the prescription, and satisfaction scores remain equivalent to immediate prescribing.
Evidence Grade & Bottom Line
Overall Evidence Grade: Strong
The evidence that paediatric antibiotic overuse is prevalent and harmful is strong — supported by large cross-sectional analyses, international surveillance data, and a clear biological mechanism linking antibiotic exposure to resistance. The evidence that stewardship interventions reduce antibiotic use without worsening outcomes is strong for inpatient settings and moderate to strong for outpatient settings. Condition-specific evidence for shorter courses and narrow-spectrum agents is strong, grounded in well-designed RCTs. The remaining gaps — primarily around community-level resistance impact and outpatient RCT evidence in high-income settings — are important but do not undermine the overall direction of the evidence.
A "strong" overall grade means that clinicians can confidently adopt stewardship-aligned practices — withholding antibiotics for viral illness, choosing narrow-spectrum agents, prescribing shorter courses — knowing that the evidence consistently supports these approaches. The question is no longer whether to practise stewardship, but how to implement it effectively within the constraints of busy clinical practice. Audit with feedback, clinical decision support, standardised order sets, and communication strategies all have supportive evidence and can be adopted incrementally.
- Approximately half of all paediatric antibiotic prescriptions are unnecessary, and only about one-third of outpatient prescriptions are optimal for both drug choice and duration.
- The highest-yield intervention is simply not prescribing antibiotics for conditions that are viral — the common cold, bronchiolitis, and non-specific URI account for the largest share of avoidable prescriptions.
- Where antibiotics are indicated, narrow-spectrum agents (primarily amoxicillin) and shorter courses (5 days for outpatient paediatric CAP) are supported by RCT evidence with equivalent outcomes and fewer adverse effects.
- Stewardship programmes — combining audit with feedback, clinical decision support, education, and standardised order sets — consistently reduce antibiotic use in paediatric inpatient settings without compromising clinical outcomes.
- Outpatient stewardship remains the primary area of need, and the direct impact of paediatric ASPs on community antimicrobial resistance rates has not been conclusively demonstrated — an important gap in the evidence that does not diminish the strength of the case for rational prescribing.
Article Information
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Lehrer BJ, Mutamba G, Thure KA, Evans CD, Hersh AL, Banerjee R, Katz SE. Optimal pediatric outpatient antibiotic prescribing. JAMA Netw Open. 2024;7(10):e2437409. DOI: 10.1001/jamanetworkopen.2024.37409
- McCulloh RJ, Kerns E, Flores R, et al. A national quality improvement collaborative to improve antibiotic use in pediatric infections. Pediatrics. 2024;153(5):e2023062246. DOI: 10.1542/peds.2023-062246
- Hersh AL, De Lurgio SA, Thurm C, et al; AAP Committee on Infectious Diseases. Antibiotic stewardship in pediatrics. Pediatrics. 2021;147(1):e2020040295. DOI: 10.1542/peds.2020-040295
- Donà D, Barbieri E, Daverio M, et al. Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review. Antimicrob Resist Infect Control. 2020;9(1):3. DOI: 10.1186/s13756-019-0659-3
- Brigadoi G, Rossin S, Visentin D, et al. The impact of antimicrobial stewardship programmes in paediatric emergency departments and primary care: a systematic review. Ther Adv Infect Dis. 2023;10:20499361221141771. DOI: 10.1177/20499361221141771
- Shao AF, Rambaud-Althaus C, Swai N, et al. A digital health algorithm to guide antibiotic prescription in pediatric outpatient care: a cluster randomized controlled trial. Nat Med. 2024;30:533-543. DOI: 10.1038/s41591-023-02633-9
- Gerber JS, Ross RK, Bryan M, et al. Association of broad- vs narrow-spectrum antibiotics with treatment failure, adverse events, and quality of life in children with acute respiratory tract infections. JAMA. 2017;318(23):2325-2336. DOI: 10.1001/jama.2017.18715
- Williams DJ, Creech CB, Walter EB, et al. Short- vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: the SCOUT-CAP randomized clinical trial. JAMA Pediatr. 2022;176(3):253-261. DOI: 10.1001/jamapediatrics.2021.5547
- Pernica JM, Harman S, Kam AJ, et al. Short-course antimicrobial therapy for pediatric community-acquired pneumonia: the SAFER randomized clinical trial. JAMA Pediatr. 2021;175(5):475-482. DOI: 10.1001/jamapediatrics.2020.6735
- Dillen H, Wouters J, Snijders D, Wynants L, Verbakel JY. Factors associated with inappropriateness of antibiotic prescriptions for acutely ill children presenting to ambulatory care in high-income countries: a systematic review and meta-analysis. J Antimicrob Chemother. 2024;79(3):498-511. DOI: 10.1093/jac/dkad401
- Tribble AC, Moorthy GS, Vartanian RJ, Smith MJ. Pediatric antimicrobial stewardship programs reduce antibiotic use at combined adult-pediatric hospitals. Clin Infect Dis. 2024;79(2):321-324. DOI: 10.1093/cid/ciae112
- Donà D, Barbieri E, Brigadoi G, et al. State of the art of antimicrobial and diagnostic stewardship in pediatric setting. Antibiotics. 2025;14(2):132. DOI: 10.3390/antibiotics14020132